News
Weekly selection of relevant developments across pharmaceuticals, medical devices, CRO-related innovation and the broader healthcare business landscape.
Open Serbian versionAn FDA advisory committee voted that the benefits of Moderna's flu vaccine outweigh its risks for adults aged 50 and older. If the FDA follows the panel's recommendation, the product could become the first mRNA-based seasonal flu vaccine cleared in the United States.
Source: AP
Paradromics said it has completed the first human implant of its Connexus brain-computer interface in a patient with severe speech impairment. The company plans to begin testing the device's communication performance as the patient recovers from the procedure.
Source: Business Insider
A new report on an ALS patient describes sustained use of an experimental brain-computer interface for communication and digital work over an extended period. The findings add to the week's neurotechnology momentum by showing how BCI systems are moving beyond initial demonstrations into longer practical use.
Source: People
Sigma Healthcare said it is no longer pursuing a potential acquisition of UK pharmacy chain Boots. The move keeps attention on capital discipline in large pharmacy retail deals and leaves the future ownership path for Boots unresolved.
Source: The Guardian
The Calvary and Pacific Equity Partners-led consortium has been given an additional two weeks to complete due diligence on a proposed Healthscope transaction. The extension reflects the complexity of carving up a large hospital network across operators, landlords and financing stakeholders.
Source: The Australian
A new preprint, AIPatient Arena, presents an EHR-grounded framework for evaluating large language models across multi-step clinical consultation workflows. While not a commercial CRO announcement, the paper is relevant for trial operations and healthcare workflow teams exploring how AI systems should be assessed before deployment.
Source: arXiv
